Clinical and socioeconomic factors associated with recurrent atrial fibrillation after catheter ablation or antiarrhythmic drug therapy

Figures

• 

  Figure 1. Cumulative incidence of recurrent atrial fibrillation (AF) after catheter ablation.

• 

  Figure 2. Cumulative incidence of recurrent atrial fibrillation (AF) after antiarrhythmic drug therapy initiation.

• 

  Figure 3. Factors associated with atrial fibrillation (AF) recurrence within 12 months after catheter ablation. Other covariates included AF therapy initiation year, prior myocardial infarction, coronary revascularization, ischemic stroke, transient ischemic attack, mitral or aortic valvular heart disease, peripheral artery disease, venous thromboembolism, dyslipidemia, chronic lung disease, liver disease, dementia, depression, cancer, high-density lipoprotein cholesterol, potassium, and urine albumin-to-creatinine ratio. A 90-day blanking period was added. CI = confidence interval; eGFR = estimated glomerular filtration rate; HR = hazard ratio; N = no; PI = Pacific Islander; Y = yes.

• 

  Figure 4. Factors associated with atrial fibrillation (AF) recurrence within 12 months after antiarrhythmic drug therapy initiation. Other covariates included AF therapy initiation year, prior myocardial infarction, coronary revascularization, ischemic stroke, transient ischemic attack, mitral or aortic valvular heart disease, peripheral arterial disease, venous thromboembolism, dyslipidemia, chronic lung disease, liver disease, dementia, depression, cancer, high-density lipoprotein cholesterol, potassium, and urine albumin-to-creatinine ratio. CI = confidence interval; eGFR = estimated glomerular filtration rate; HR = hazard ratio; N = no; PI = Pacific Islander; Y = yes.